恶性肿瘤的分期越高，患者预后越差。通过对肿瘤不同恶性程度的划分，TNM分期在预测预后方面不断完善。&&&&&&预后:0.34847839056318075@@分期:0.3241050495196862@@不断完善:0.26109204606462993@@划分:0.26109204606462993@@恶性:0.26109204606462993@@恶性肿瘤:0.26109204606462993@@方面:0.26109204606462993@@程度:0.26109204606462993@@越差:0.26109204606462993@@越高:0.26109204606462993@@不同:0.22903724302311207@@肿瘤:0.22903724302311207@@通过:0.22903724302311207@@预测:0.17423919528159038@@
但是有国外研究发现，部分结肠癌的预后并不能完全按照一般的分期阶梯进行预测。&&&&&&一般:0.2948794911485365@@不能:0.2948794911485365@@但是:0.2948794911485365@@国外:0.2948794911485365@@完全:0.2948794911485365@@按照:0.2948794911485365@@部分:0.2948794911485365@@阶梯:0.2948794911485365@@发现:0.2586765345582406@@进行:0.23299012807711905@@研究:0.19678717148682312@@预后:0.19678717148682312@@预测:0.19678717148682312@@分期:0.18302344617840008@@结肠癌:0.18302344617840008@@
TNM期不太能明确地区分（II期和III期结肠癌患者的预后，特别是在接受辅助化疗的患者中，他们的5年总生存期在50.9%-90.1%。&&&&&&患者:0.3109782767756885@@50:0.2855234434871185@@90:0.2855234434871185@@不太能:0.2855234434871185@@他们:0.2855234434871185@@地区:0.2855234434871185@@明确:0.2855234434871185@@特别:0.2504691479516276@@iii期:0.22559772945882597@@ii期:0.22559772945882597@@生存期:0.2063059585069329@@辅助:0.2063059585069329@@化疗:0.1905434339233351@@接受:0.1905434339233351@@预后:0.1905434339233351@@结肠癌:0.1772164092802676@@tnm:0.15548913838784426@@
此外已知影响结肠癌生存的患者或疾病特征，包括年龄、性别、原发疾病位置、肿瘤分级、阳性淋巴结数目（LNs）、接受检查的&&&&&&疾病:0.44166816802745645@@位置:0.22083408401372823@@分级:0.22083408401372823@@原发:0.22083408401372823@@已知:0.22083408401372823@@年龄:0.22083408401372823@@影响:0.22083408401372823@@性别:0.22083408401372823@@检查:0.22083408401372823@@此外:0.22083408401372823@@淋巴结:0.22083408401372823@@生存:0.22083408401372823@@阳性:0.22083408401372823@@lns:0.19372183308685853@@数目:0.19372183308685853@@肿瘤:0.19372183308685853@@包括:0.17448538492029056@@
LNs数目、淋巴管和周围神经浸润、肠道梗阻或穿孔、以及辅助治疗（氟尿嘧啶单药或联合奥沙利铂），并未直接纳入TNM分期系统。&&&&&&单药:0.2421608665669062@@周围神经:0.2421608665669062@@奥沙利铂:0.2421608665669062@@并未:0.2421608665669062@@梗阻:0.2421608665669062@@氟尿嘧啶:0.2421608665669062@@浸润:0.2421608665669062@@淋巴管:0.2421608665669062@@直接:0.2421608665669062@@穿孔:0.2421608665669062@@肠道:0.2421608665669062@@lns:0.21243028304601264@@以及:0.21243028304601264@@数目:0.21243028304601264@@治疗:0.21243028304601264@@系统:0.1913360983394712@@纳入:0.1913360983394712@@联合:0.17497417753092132@@辅助:0.17497417753092132@@分期:0.15030247154861465@@
在多变量模型中，分子标记的微卫星不稳定性（MSI）和BRAF或KRAS基因突变联合详细的临床病理学诠释可以多大程度改善预后评估&&&&&&braf:0.25690130073117606@@不稳定性:0.25690130073117606@@大程度:0.25690130073117606@@微卫星:0.25690130073117606@@改善:0.25690130073117606@@病理学:0.25690130073117606@@评估:0.25690130073117606@@诠释:0.25690130073117606@@详细:0.25690130073117606@@kras:0.2253610040420569@@可以:0.2253610040420569@@msi:0.20298280740855196@@基因突变:0.20298280740855196@@分子:0.18562492957400265@@多变量:0.18562492957400265@@标记:0.18562492957400265@@联合:0.18562492957400265@@临床:0.1714425107194328@@预后:0.1714425107194328@@模型:0.15945144643460135@@
目前尚不清楚。近期，发表在Annalsofoncology杂志上的一项回顾性研究，在TNM分期系统基础上联合汇集的标志物对II期和III期&&&&&&annals:0.24601827189600917@@of:0.24601827189600917@@oncology:0.24601827189600917@@一项:0.24601827189600917@@发表:0.24601827189600917@@回顾性:0.24601827189600917@@基础:0.24601827189600917@@杂志:0.24601827189600917@@标志物:0.24601827189600917@@汇集:0.24601827189600917@@清楚:0.24601827189600917@@目前:0.24601827189600917@@近期:0.24601827189600917@@iii期:0.19438391071249364@@ii期:0.19438391071249364@@系统:0.19438391071249364@@联合:0.1777613591859585@@研究:0.16417974567144497@@分期:0.15269665506368227@@
结肠癌总生存期进行预测。&&&&&&进行:0.5619453082412887@@生存期:0.5138911004259548@@预测:0.474627953775326@@结肠癌:0.4414314362884129@@
研究人员将缺失随机数据插补后，利用3期辅助化疗试验（n=3016）—N0147（NCT00079274）和PETACC3（NCT00026273）—产生的患者亚组&&&&&&3016:0.24463590099984192@@3期:0.24463590099984192@@n0147:0.24463590099984192@@nct00026273:0.24463590099984192@@nct00079274:0.24463590099984192@@petacc3:0.24463590099984192@@亚组:0.24463590099984192@@产生:0.24463590099984192@@人员:0.24463590099984192@@利用:0.24463590099984192@@插补后:0.24463590099984192@@数据:0.24463590099984192@@缺失:0.24463590099984192@@试验:0.24463590099984192@@随机:0.24463590099984192@@辅助:0.17676252228043926@@化疗:0.16325722353352717@@研究:0.16325722353352717@@
聚集构建了一个5年总生存期多变量Cox模型，随后在剩余的临床试验样本（n=1499）中进行内部验证，并且还在不同人群队列中外部分析，&&&&&&1499:0.23800155863904213@@cox:0.23800155863904213@@一个:0.23800155863904213@@人群:0.23800155863904213@@内部:0.23800155863904213@@剩余:0.23800155863904213@@外部:0.23800155863904213@@并且:0.23800155863904213@@构建:0.23800155863904213@@样本:0.23800155863904213@@聚集:0.23800155863904213@@随后:0.23800155863904213@@不同:0.20878162183614055@@临床试验:0.20878162183614055@@分析:0.20878162183614055@@验证:0.20878162183614055@@进行:0.18804974674190594@@多变量:0.17196885510168902@@生存期:0.17196885510168902@@队列:0.17196885510168902@@
包括接受化疗（n=949）或者未接受化疗（n=1080）的结肠癌患者，以及没有治疗注释患者。&&&&&&化疗:0.38421934238532535@@接受:0.38421934238532535@@患者:0.31353446964472914@@1080:0.28787040160185573@@949:0.28787040160185573@@或者:0.28787040160185573@@没有:0.28787040160185573@@以及:0.2525279652315576@@治疗:0.2525279652315576@@注释:0.2525279652315576@@包括:0.2274521075629608@@结肠癌:0.17867310048833537@@
研究分析发现：&&&&&&分析:0.6227255294799102@@发现:0.6227255294799102@@研究:0.47373603395554675@@
在根据临床试验队列和观察性研究做出的多变量模型中，TMN分期，MSI和BRAFV600E基因突变状态仍然是独立预后因素。&&&&&&tmn:0.2745915722532637@@仍然:0.2745915722532637@@做出:0.2745915722532637@@因素:0.2745915722532637@@根据:0.2745915722532637@@独立:0.2745915722532637@@观察:0.2745915722532637@@brafv600e:0.24087940484675346@@临床试验:0.24087940484675346@@状态:0.24087940484675346@@msi:0.21696024141590398@@基因突变:0.21696024141590398@@多变量:0.19840709687360947@@队列:0.19840709687360947@@研究:0.18324807400939375@@预后:0.18324807400939375@@分期:0.17043130279963145@@模型:0.17043130279963145@@
单纯TNM模型的一致性指数（Concordance-indices）为0.61-0.68，而增加分子标记物、临床病理特征和所有协变量后的&&&&&&61:0.28630040505767573@@68:0.28630040505767573@@concordance:0.28630040505767573@@indices:0.28630040505767573@@单纯:0.28630040505767573@@变量:0.28630040505767573@@所有:0.28630040505767573@@一致性:0.25115072036540875@@指数:0.25115072036540875@@分子:0.20686735479572516@@增加:0.20686735479572516@@标记:0.20686735479572516@@病理:0.20686735479572516@@临床:0.19106193749653508@@特征:0.19106193749653508@@模型:0.17769864757916623@@tnm:0.15591225280426818@@
一致性指数分别增加至0.63-0.71、0.65-0.73和0.66-0.74。&&&&&&63:0.34099322230765833@@66:0.34099322230765833@@71:0.34099322230765833@@73:0.34099322230765833@@74:0.34099322230765833@@65:0.29912878888535943@@一致性:0.29912878888535943@@分别:0.29912878888535943@@指数:0.29912878888535943@@增加:0.24638584038274572@@
在有完整注释的验证队列中，单独TNM的综合时间依赖AUC值为0.64，纳入临床病理特征联合或不联合分子标记物的AUC增加为0.67。&&&&&&auc:0.4466626669754543@@联合:0.3227376656508817@@64:0.22333133348772716@@67:0.22333133348772716@@依赖:0.22333133348772716@@值为:0.22333133348772716@@单独:0.22333133348772716@@完整:0.22333133348772716@@时间:0.22333133348772716@@综合:0.22333133348772716@@注释:0.19591249014932627@@验证:0.19591249014932627@@纳入:0.17645851120493425@@分子:0.16136883282544084@@增加:0.16136883282544084@@标记:0.16136883282544084@@病理:0.16136883282544084@@队列:0.16136883282544084@@
在接受辅助化疗的患者队列中，通过TNM、临床病理特征和分子标记物的方差（R2）相对比例平均值分别为65.0%、25%和10%。&&&&&&10:0.2645026751066168@@25:0.2645026751066168@@r2:0.2645026751066168@@平均值:0.2645026751066168@@方差:0.2645026751066168@@比例:0.2645026751066168@@相对:0.2645026751066168@@65:0.23202914218099707@@分别:0.23202914218099707@@通过:0.23202914218099707@@分子:0.1911173291028914@@标记:0.1911173291028914@@病理:0.1911173291028914@@辅助:0.1911173291028914@@队列:0.1911173291028914@@临床:0.17651527097457687@@化疗:0.17651527097457687@@接受:0.17651527097457687@@特征:0.17651527097457687@@
因此，将MSI、BRAFV600E和KRAS基因突变状态纳入TNM分期系统的总生存期模型可以提高精确预测II期和III期结肠癌患者的能力，&&&&&&因此:0.27176206102591255@@提高:0.27176206102591255@@精确:0.27176206102591255@@能力:0.27176206102591255@@brafv600e:0.23839727848410266@@kras:0.23839727848410266@@可以:0.23839727848410266@@状态:0.23839727848410266@@iii期:0.21472458853720272@@ii期:0.21472458853720272@@msi:0.21472458853720272@@基因突变:0.21472458853720272@@系统:0.21472458853720272@@纳入:0.21472458853720272@@生存期:0.19636262368172203@@预测:0.18135980599539284@@分期:0.16867510438171765@@模型:0.16867510438171765@@结肠癌:0.16867510438171765@@
而且包括临床病理特征的多变量模型中会增加预测准确性，特别是需要接受化疗的患者。&&&&&&准确性:0.3357930619795986@@而且:0.3357930619795986@@需要:0.3357930619795986@@特别:0.2945670628474772@@包括:0.2653167509659918@@增加:0.24262844642669215@@多变量:0.24262844642669215@@病理:0.24262844642669215@@临床:0.22409075183387042@@化疗:0.22409075183387042@@接受:0.22409075183387042@@特征:0.22409075183387042@@预测:0.22409075183387042@@模型:0.20841735438069386@@患者:0.1828647527017491@@
